Acalabrutinib Maleate

證據等級: L5

預測適應症: 0 個

Acalabrutinib Maleate: Drug Repurposing Evaluation Report

One-Sentence Summary

Acalabrutinib maleate is a second-generation BTK (Bruton’s Tyrosine Kinase) inhibitor, currently not marketed in Taiwan, with no recorded approvals in the local regulatory database. This Evidence Pack contains no TxGNN-predicted indications and is missing critical baseline data including mechanism of action details and safety information. As a result, a full repurposing evaluation cannot be completed with the current data — this report serves as a gap assessment and readiness checklist.

Quick Overview

Item	Content
Original Indication	Not recorded in Evidence Pack
Predicted New Indication	None — TxGNN predictions not available
TxGNN Prediction Score	N/A
Evidence Level	N/A (no predictions generated)
Taiwan Market Status	Not marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why Predictions Are Unavailable

The Evidence Pack returned an empty predicted_indications array, which indicates the TxGNN prediction pipeline was not completed for this candidate. Two likely causes:

Missing DrugBank ID: The drugbank_id field is null, which means the drug could not be matched to a node in the TxGNN knowledge graph. Without a valid DrugBank entry, neither the Knowledge Graph (KG) method nor the Deep Learning (DL) method can generate repurposing candidates.
Incomplete data inputs: The inputs_received field in the metadata is empty ([]), confirming that the pipeline did not receive the necessary input files to run predictions.

Acalabrutinib maleate is the maleate salt form of acalabrutinib (brand name: Calquence, AstraZeneca). The free base form may already exist in DrugBank under a separate entry. Resolving the DrugBank mapping is the single most critical step to unlock TxGNN predictions for this drug.

Taiwan Market Information

Item	Content
Market Status	Not marketed in Taiwan
Total Licenses	0
Dosage Forms	No records

No TFDA marketing authorizations were found for acalabrutinib maleate. The drug may be available through compassionate use or clinical trial access in Taiwan, but this is not reflected in the current Evidence Pack.

Safety Considerations

No safety data is available in this Evidence Pack. Please refer to the prescribing information (SmPC or USPI for Calquence) for:

Haemorrhage risk (major bleeding events)
Atrial fibrillation / atrial flutter
Infections (including opportunistic infections)
Cytopenias
Second primary malignancies
Drug interactions via CYP3A pathway

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy — selective BTK inhibitor (kinase inhibitor class)
Myelosuppression Risk	Moderate (neutropenia, anaemia, and thrombocytopenia reported)
Emetogenicity Classification	Low
Monitoring Items	CBC with differential, hepatic function, cardiac monitoring (ECG for AF), bleeding assessment
Handling Protection	Handle per institutional cytotoxic drug handling protocols for oral targeted agents

Note: Classification is based on drug class knowledge. Formal toxicity data was not available in the Evidence Pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is critically incomplete — no DrugBank ID, no TxGNN predictions, no safety records, and no regulatory authorizations. A repurposing evaluation cannot be responsibly conducted without resolving these foundational data gaps.

To proceed, the following is needed:

Resolve DrugBank ID: Search DrugBank for “acalabrutinib” (free base, DB12493) and confirm whether the maleate salt maps to the same node; update drugbank_id in the candidate record
Re-run TxGNN pipeline: With a valid DrugBank ID, re-execute both the KG and DL prediction modules to generate repurposing candidates
Retrieve TFDA prescribing information: Download and parse the SmPC/仿單 PDF from the TFDA website to populate safety warnings and contraindications (Data Gap DG001 — Blocking)
Retrieve mechanism of action: Query the DrugBank API for MOA, pharmacodynamics, and pharmacokinetics data (Data Gap DG002 — High)
Check EU / FDA approvals: Acalabrutinib holds FDA approval for CLL/SLL and MCL; confirm whether EMA authorization exists and populate regulatory context accordingly
Re-generate Evidence Pack: Once the above inputs are resolved, re-run the full evidence collection pipeline (ClinicalTrials.gov + PubMed) against the top TxGNN-predicted indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.